Regulatory press release01.08.2024 klo 09.45The subscription period in Cyxone's rights issue starts today
Regulatory press release23.07.2024 klo 09.30Cyxone: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Press release20.11.2023 klo 10.22Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor
Regulatory press release09.10.2023 klo 09.38Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K
Regulatory press release29.08.2023 klo 20.03Cyxone revises strategy for commercial alignment targeting valuable market opportunities
Press release31.05.2023 klo 15.00Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K